Arcus Biosciences
RCUS
186 hedge funds and large institutions have $1.25B invested in Arcus Biosciences in 2024 Q4 according to their latest regulatory filings, with 25 funds opening new positions, 61 increasing their positions, 67 reducing their positions, and 24 closing their positions.
144% more call options, than puts
Call options by funds: $5.08M | Put options by funds: $2.08M
53% more capital invested
Capital invested by funds: $816M → $1.25B (+$434M)
33.37% more ownership
Funds ownership: 58.34% → 91.71% (+33%)
4% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 24
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
1% less funds holding
Funds holding: 187 → 186 (-1)
9% less repeat investments, than reductions
Existing positions increased: 61 | Existing positions reduced: 67
Top Buyers
| 1 |
B
Braidwell
Stamford,
Connecticut
|
+$13.1M |
| 2 |
Millennium Management
New York
|
+$11.1M |
| 3 |
BNP Paribas Asset Management
Paris,
France
|
+$9.65M |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$7.6M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
+$7.23M |
Top Sellers
| 1 |
AllianceBernstein
Nashville,
Tennessee
|
-$20.1M |
| 2 |
SSA
Schonfeld Strategic Advisors
New York
|
-$8.8M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$7.2M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$6.78M |
| 5 |
IC
Ikarian Capital
Dallas,
Texas
|
-$5.97M |
RCUS Hedge Fund Activity: Q4 2024 in Review
186 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Arcus Biosciences (RCUS) for Q4 2024, worth a combined $1.25B — up 53% from $816M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new RCUS positions and 24 closed out — a net gain of 1 holder — while 61 added to existing stakes and 67 trimmed.
The largest buyer was Braidwell, opening a new position worth an estimated $13.1M. The largest seller was AllianceBernstein, cutting an estimated $20.1M.
- 186 institutional investors held Arcus Biosciences (RCUS) as of Q4 2024, down from 187 in Q3 2024.
- Funds reported $1.25B of Arcus Biosciences stock for Q4 2024, up 53% quarter-over-quarter.
- 25 funds opened new Arcus Biosciences positions in Q4 2024 and 24 closed out, a net change of +1 holder.
- The largest Arcus Biosciences buyer in Q4 2024 was Braidwell, an estimated $13.1M added.
- The largest Arcus Biosciences seller in Q4 2024 was AllianceBernstein, an estimated $20.1M sold.
Based on aggregated 13F filings for Q4 2024.